Atraverse Medical Announces First Clinical Use of HOTWIRE™ Radiofrequency (RF) Guidewire System at St. Bernards Medical Center

Atraverse Medical HOTWIRE™ RF guidewire device has been used for the first time in clinical practice by world-renowned cardiac electrophysiologist, Dr. Devi Nair, at St. Bernards Medical Center. The best-in-class left-heart access device received FDA 510(k) clearance earlier this year and was unveiled at the Heart Rhythm Society congress in May.

Co-founded by Dr. Steven Mickelsen, the pioneer of Farapulse pulsed field ablation technology, Atraverse’s HOTWIRE™ device is a novel radiofrequency (RF) guidewire that enables zero exchange left-heart access while acting as a rail for catheter-based therapy systems. Featuring universal sheath compatibility, the HOTWIRE™ is designed to improve patient outcomes and streamline procedural workflows.

“We are thrilled to use the HOTWIRE™ in our clinical practice and are proud to be first in the world to utilize this innovative technology,” commented Dr. Nair, who performed twelve cases after crossing the septum with the HOTWIRE™, including four atrial fibrillation ablation procedures and eight left atrial appendage closures, while utilizing five different models of transseptal sheaths. “We have been eagerly awaiting a sheath-agnostic solution like this, and we look forward to using the product in a majority of our cases going forward for left atrial access.”

Eric Sauter, COO and Co-Founder for Atraverse Medical, commented…

“Our mission is to improve efficiency and take the guesswork out of what should be simply-executed therapeutic and diagnostic procedures. Our collaboration with Dr. Nair exemplifies our dedication to taking patient care to the next level with innovative technologies.”

In addition, the company has strengthened its executive leadership team with two industry veterans in support of its commercialization plan. Jay Kelley, MBA, who joined the Atraverse Medical team as Vice President of Marketing in 2023, has been promoted to Chief Marketing Officer.  Mr. Kelley has been instrumental in the development of Atraverse’s commercialization strategy to drive market adoption with a focused launch. He has more than 20 years of medical device R&D and commercialization experience, primarily focused on cardiac electrophysiology.

Most recently, in May of 2024, Brandon Allen joined Atraverse as Vice President of Sales.  Mr. Allen brings two decades of experience in the cardiac electrophysiology space, serving with market leaders including Biosense and Guidant / Boston Scientific, and has propelled the company forward following the FDA 510(k) clearance of the HOTWIRE™.

“Our HOTWIRE™ device has gained the attention of several thought leaders in the field, and we are excited to have Jay and Brandon on the team leading commercialization efforts,” noted John Slump, CEO and Co-Founder of Atraverse Medical. “Their deep experience and impeccable reputations are a tremendous asset to our company.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”